ConverGene Announces Sponsored Research Agreement with MD Anderson

ConverGene Announces Sponsored Research Agreement with MD Anderson

CAMBRIDGE, Md., Sept. 18, 2017 (GLOBE NEWSWIRE) — ConverGene is pleased to announce that it has entered into a collaboration with The University of Texas MD Anderson Cancer Center (“MD Anderson”) to characterize ConverGene’s first-in-class dual inhibitor of BET bromodomains and dopamine receptor 2, in ovarian carcinoma. Work will be done under the guidance of Dr. Sherry Wu in the laboratory of Dr. Anil Sood. The program will advance in 2 distinct phases.

Click here to read more.

URL link to full story
http://convergenepharma.com/convergene-announces-sponsored-research-agreement-md-anderson/
Media Contact
Dr. Elizabeth Smith
(240) 207-4520
Comments are closed.